港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

映恩生物-B

215.600

+8.2003.95%

成交量：21.58萬

成交額：4,641.99萬

市值：184.20億

市盈率：-1.53

高：219.600

開：207.400

低：202.400

收：207.400

資料載入中...

總覽公司新聞公告

映恩生物今起招股：獲十餘家機構超5億港元基石認購，擁有12條ADC管線

Ofweek维科网

新股招股 | 創新藥研發商映恩生物-B今起招股，入場費10424港元

老虎资讯综合

映恩生物製藥（蘇州）有限公司藥品申請臨牀試驗默示許可獲受理

南開“學霸”朱忠遠攢出一個IPO，映恩生物通過港交所聆訊，2年達成60億美元BD

映恩生物今日啓動PDIE，致力於癌症及免疫性疾病的ADC藥物研發

独角兽早知道

映恩生物虧損大幅加劇：無商業化經營成本高漲，負債總值超40億

新股消息 | 映恩生物通過港交所聆訊，致力於癌症及免疫性疾病的ADC藥物研發

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09606/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":215.6,"timestamp":1746173305036,"preClose":207.4,"halted":0,"volume":215800,"delay":0,"floatShares":85436500,"shares":85436464,"eps":-141.11298178002352,"marketStatus":"休市中","change":8.2,"latestTime":"05-02 16:08:25","open":207.4,"high":219.6,"low":202.4,"amount":46419870,"amplitude":0.082932,"askPrice":215.8,"askSize":100,"bidPrice":215.6,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-141.11299252704754,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746495000000},"marketStatusCode":7,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":207.4,"openAndCloseTimeList":[[1746149400000,1746158400000],[1746162000000,1746172800000]],"volumeRatio":0.4018063784508292,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":85436500,"roa":"-6.51%","roe":"--","lyrEps":-141.112993,"volumeRatio":0.4018063784508292,"shares":85436464,"dividePrice":0,"high":219.6,"amplitude":0.082932,"preClose":207.4,"low":202.4,"week52Low":178.8,"pbRate":"-8.45","psRate":"8.83","week52High":234.6,"institutionHeld":0,"latestPrice":215.6,"committee":0.333333,"eps":-141.11298178002352,"divideRate":0,"volume":215800,"delay":0,"ttmEps":-141.11299252704754,"open":207.4,"prevYearClose":94.6,"prevWeekClose":207.4,"prevMonthClose":207.4,"prevQuarterClose":94.6,"fiveDayClose":225,"twentyDayClose":94.6,"sixtyDayClose":94.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525211080","title":"映恩生物今起招股：獲十餘家機構超5億港元基石認購，擁有12條ADC管線","url":"https://stock-news.laohu8.com/highlight/detail?id=2525211080","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525211080?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 15:46","pubTimestamp":1744012009,"startTime":"0","endTime":"0","summary":"映恩生物计划在本次IPO中发行15,071,600股股份。以每股94.60港元至103.20港元的发行价计算，映恩生物的IPO市值介于78.68亿港元至85.84亿港元。成立于2019年的映恩生物致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。目前，映恩生物已建立由12款自主研发的ADC候选药物组成的管线，涵盖七款临床阶段ADC、两款新一代双特异性ADC预计将于2025 年至2026年进入临床阶段以及多款其他临床前ADC。2023年和2024年，映恩生物的营收分别为17.87亿元和19.41亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040715465797307012&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025040715465797307012&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09606"],"gpt_icon":1},{"id":"1145008053","title":"新股招股 | 創新藥研發商映恩生物-B今起招股，入場費10424港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145008053","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145008053?lang=zh_tw&edition=fundamental","pubTime":"2025-04-07 08:30","pubTimestamp":1743985850,"startTime":"0","endTime":"0","summary":"创新药研发商 $映恩生物－Ｂ$ 于4月7日至4月10日招股，公司拟全球发售1507.16万股股份，预期将于4月15日上市，入场费10424港元。映恩生物于2019年注册成立，主营业务在全球抗体偶联药物领域，致力于为癌症和自身免疫性疾病等患者研发ADC创新药物。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"新股招股 | 创新药研发商映恩生物-B今起招股，入场费10424港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":1},{"id":"2524482315","title":"映恩生物製藥（蘇州）有限公司藥品申請臨牀試驗默示許可獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2524482315","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524482315?lang=zh_tw&edition=fundamental","pubTime":"2025-04-02 13:54","pubTimestamp":1743573280,"startTime":"0","endTime":"0","summary":"4月2日，据CDE官网消息，映恩生物制药（苏州）有限公司联合申请药品“注射用DB-1310”，获得临床试验默示许可，受理号CXSB2500002。映恩生物制药（苏州）有限公司，成立于2020年，位于苏州市，是一家以从事医药制造业为主的企业。主要股东信息显示，映恩生物制药（苏州）有限公司由DUALITYBIO HK LIMITED持股100%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/04/02135449241309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["09606","BK1576","03347","BK1583","BK1141"],"gpt_icon":0},{"id":"2522043135","title":"南開“學霸”朱忠遠攢出一個IPO，映恩生物通過港交所聆訊，2年達成60億美元BD","url":"https://stock-news.laohu8.com/highlight/detail?id=2522043135","media":"时代财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522043135?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 17:52","pubTimestamp":1742896357,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tfcaijing.com/article/page/7a56756c417830567350636631594a666f47437454513d3d","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tf_highlight","symbols":["09606"],"gpt_icon":0},{"id":"1102406340","title":"映恩生物今日啓動PDIE，致力於癌症及免疫性疾病的ADC藥物研發","url":"https://stock-news.laohu8.com/highlight/detail?id=1102406340","media":"独角兽早知道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102406340?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 09:16","pubTimestamp":1742865369,"startTime":"0","endTime":"0","summary":"据“独角兽早知道”独家消息源，映恩生物今日启动PDIE，此前已通过港交所聆讯，Morgan Stanley、Jefferies、CITIC Securities为联席保荐人。据招股书，公司于2019年注册成立，是抗体偶联药物领域的全球领跑者，致力于为癌症和自身免疫性疾病等患者研发新一代ADC创新药物。截至2月19日，公司尚未获得任何候选药物的上市批准，亦未从产品销售中获得任何收入。","market":"hk","thumbnail":"https://static.tigerbbs.com/fd198241dae71f50746183c8cdcca405","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd198241dae71f50746183c8cdcca405"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"gpt_icon":0},{"id":"2522003567","title":"映恩生物虧損大幅加劇：無商業化經營成本高漲，負債總值超40億","url":"https://stock-news.laohu8.com/highlight/detail?id=2522003567","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522003567?lang=zh_tw&edition=fundamental","pubTime":"2025-03-25 08:20","pubTimestamp":1742862000,"startTime":"0","endTime":"0","summary":null,"market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2025-03-25/doc-ineqvkuy2864922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606"],"gpt_icon":0},{"id":"2521478293","title":"新股消息 | 映恩生物通過港交所聆訊，致力於癌症及免疫性疾病的ADC藥物研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2521478293","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521478293?lang=zh_tw&edition=fundamental","pubTime":"2025-03-24 07:16","pubTimestamp":1742771795,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所3月23日披露，映恩生物通过港交所上市聆讯，Morgan Stanley、Jefferies、CITIC Securities为其联席保荐人。据招股书，公司于2019年注册成立，是抗体偶联药物领域的全球领跑者，致力于为癌症和自身免疫性疾病等患者研发新一代ADC创新药物。截至2月19日，公司尚未获得任何候选药物的上市批准，亦未从产品销售中获得任何收入。预计公司的后期ADC将在未来几年实现商业化，公司计划通过选择最佳商业模式使候选药物的商业价值最大化。","market":"us","thumbnail":"https://static.tigerbbs.com/0bc9411b92daca5fa6f9496d92394df3","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0bc9411b92daca5fa6f9496d92394df3"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1266076.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4231","09606","BK4080"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":67,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2025-05-02","current":-16.438538,"percent":0.363636,"low":-17.183112,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"high":-7.368305,"avg":-15.276848,"sd":2.537961,"marketCap":18420101638},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638}],"updateTime":1746247900859}}}